[Biological treatments in pediatric IBD]

Area of Science:

• Pediatric Gastroenterology
• Immunology
• Pharmacology

Background:

• Inflammatory bowel disease (IBD) affects approximately 1,500 children in Sweden.
• Biological therapies represent a significant treatment modality for pediatric IBD.
• Understanding current biologic utilization patterns and associated adverse events is crucial for optimizing patient care.

Purpose of the Study:

• To investigate the prevalence and patterns of biological treatment use in pediatric IBD patients in Sweden.
• To identify the specific biological agents most commonly prescribed.
• To document the frequency and nature of adverse events associated with these treatments.

Main Methods:

• A nationwide survey was distributed to pediatric gastroenterologists across Sweden.
• Data were collected on the number of pediatric IBD patients and their ongoing biological treatments.
• Information on specific biologic agents used and reported side effects was gathered.

Main Results:

• Out of 1,098 recorded pediatric IBD patients, 17% were receiving biological treatment.
• Infliximab and adalimumab (both anti-TNF-alpha agents) were the predominant biologics used.
• Significant variation in biologic prescribing practices was observed among responders.

Conclusions:

• Biological therapies, particularly anti-TNF-alpha agents, are utilized in a notable proportion of pediatric IBD patients in Sweden.
• The observed variability in treatment suggests potential differences in clinical practice or patient selection.
• Anaphylactic and infusion reactions were the most common adverse events, highlighting the need for careful monitoring during biologic administration.